Log in to search using one of your social media accounts:

 

TUDORZA PRESSAIR (Aclidinium Bromide) Inhalant [AstraZeneca Pharmaceuticals LP]
Updated Date: Jul 1, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 1, 2015 Category: Drugs & Pharmacology Source Type: news

Aclidinium bromide/formoterol in COPD: Added benefit for certain patient groups
Patients with COPD grade III with no more than one flare-up per year and grade II patients benefit from the new aclidinium Bromide/formoterol drug combination, researchers note. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2015 Category: Science Source Type: news

Federal Register: Determination of Regulatory Review Period for Purposes of Patent Extension; TUDORZA PRESSAIR
The FDA has determined the regulatory review period for TUDORZA PRESSAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 4, 2015 Category: Medical Equipment Source Type: news

Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - December 10, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca obtains European approval for Duaklir Genuair to treat COPD
British-Swedish drugmaker AstraZeneca has received marketing approval from the European Commission (EC) for Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12mcg). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 24, 2014 Category: Pharmaceuticals Source Type: news

Benefits of Aclidinium Persist to 1 Year for COPDBenefits of Aclidinium Persist to 1 Year for COPD
The long-acting muscarinic receptor antagonist aclidinium bromide continued to be effective for up to 52 weeks, according to the ACCORD COPD II extension study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

EC's CHMP Recommends Combo Inhalers for COPD, AsthmaEC's CHMP Recommends Combo Inhalers for COPD, Asthma
The committee has endorsed the combination of aclidinium bromide/formoterol fumarate for COPD, and a budesonide/formoterol combination for COPD and asthma. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

Bronchodilator Combo Works Best for COPD
CHICAGO (MedPage Today) -- Combining formoterol (Foradil Aerolizer) and aclidinium (Tudorza Pressair) in a single twice-daily inhaler was better than either drug alone in chronic obstructive pulmonary disease, a randomized trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - October 31, 2013 Category: Journals (General) Source Type: news

Added benefit of aclidinium bromide is not proven
(Institute for Quality and Efficiency in Health Care) In an early benefit assessment IQWiG examined whether aclidinium bromide alleviates symptoms of chronic-obstructive pulmonary disease better than conventional drugs. However, such an added benefit cannot be inferred from the drug manufacturer's dossier as it does not provide robust results. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2013 Category: Global & Universal Source Type: news

Aclidinium Bromide, New Anticholinergic, for Managing COPDAclidinium Bromide, New Anticholinergic, for Managing COPD
Learn more about a new key player in COPD management. Therapeutic Advances in Respiratory Disease (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

NICE evidence summary (new medicines) on aclidinium bromide for chronic obstructive pulmonary disease
Source: NICE Area: Evidence> Drug Specific Reviews 'Evidence summaries: new medicines' are provided to help commissioners, budget holders and groups such as Area Prescribing Committees to make informed decisions and aid local planning on the introduction of key new medicines. They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, that are considered to be of significance to the NHS. The topics selected are medicines that have recently gone into the UK market, or medicines that may be marketed in the UK in the next 6-...
Source: NeLM - Drug Specific Reviews - January 7, 2013 Category: Drugs & Pharmacology Source Type: news